FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine. A composition for treating an ear disease is introduced into the tympanic cavity, contains a polyoxyethylene-polyoxypropylene copolymer, an active substance specified in an immunomodulator, a vasopressin antagonist, an ion channel antagonist, a neurokinin receptor antagonist, a serotonin reuptake inhibitor, an NMDA-receptor antagonist, a prostaglandin analogue, a preparation having an effect on the central nervous system, a GABA receptor modulator, a cytotoxic agent, an antioxidant, a glutamate receptor modulator or a calcineurin inhibitor.
EFFECT: invention provides the prolonged release of the active substance into the internal ear for a period of time of at least 7 days.
14 cl, 3 dwg, 114 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APOPTOSIS MODULATING COMPOSITIONS WITH CONTROLLED RELEASE AND METHODS OF TREATING EAR DISEASES | 2009 |
|
RU2493828C2 |
| ANTICANCER VACCINE COMPOSITION CONTAINING WT1 PEPTIDE FOR TRANSDERMAL ADMINISTRATION | 2014 |
|
RU2687144C2 |
| APPLICATION OF NKG2D INHIBITORS FOR TREATING CARDIOVASCULAR AND METABOLIC DISEASES SUCH AS TYPE 2 DIABETES | 2010 |
|
RU2566264C2 |
| ANTICANCER VACCINE COMPOSITION CONTAINING PEPTIDE WT1 FOR TRANSDERMAL ADMINISTRATION | 2014 |
|
RU2685933C2 |
| ORGANIC COMPOUNDS | 2015 |
|
RU2785871C2 |
| ANTI-CANCER VACCINE PREPARATION CONTAINING PEPTIDE WT1 IN THE FORM OF A TRANSDERMAL INTRODUCTION TAPE | 2014 |
|
RU2697443C2 |
| ORGANIC COMPOUNDS | 2015 |
|
RU2728787C2 |
| PEPTIDE ANTAGONIST OF THE NMDA RECEPTOR | 2019 |
|
RU2716258C1 |
| COMPOSITION AND METHOD FOR TREATMENT OF EYE DISEASE ASSICIATED WITH NUCLEIC ACIDS | 2012 |
|
RU2642609C2 |
| METHODS AND COMPOSITIONS FOR TREATING DRY EYE DISEASE AND OTHER EYE DISEASES | 2016 |
|
RU2691412C2 |
